| abstract |
For example, an external preparation comprising as an active ingredient 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1~-cyclopentane] of formula (I) or a pharmacologically acceptable salt thereof, wherein a solvent component in which the solubility of the active ingredient is >= 4 mg/mL is contained in an amount of 0.5 to 15 mass%. |